Antifungal activity of topical microemulsion containing a thiophene derivative

Geovani Pereira Guimarães¹, Mysrayn Yargo de Freitas Araújo Reis², Dayanne Tomaz Casimiro da Silva², Francisco Jaime Bezerra Mendonça Junior¹,³, Attílio Converti⁴, Adalberto Pessoa Jr⁵, Bolívar Ponciano Goulart de Lima Damasceno¹,², José Alexsandro da Silva¹,²

¹Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Estadual da Paraíba, Campina Grande, PB, Brazil.
²Departmento de Farmácia, Universidade Estadual da Paraíba, Campina Grande, PB, Brazil.
³Laboratório de Síntese e Vetorização de Moléculas, Departamento de Ciências Biológicas, Universidade Estadual da Paraíba, João Pessoa, PB, Brazil.
⁴Department of Civil, Chemical and Environmental Engineering, Chemical Engineering Pole, Genoa University, Genova, Italy.
⁵Departmento de Tecnologia Bioquímico-Farmacêutica, Universidade de São Paulo, São Paulo, SP, Brazil.

Submitted: April 11, 2013; Approved: September 9, 2013.

Abstract

Fungal infections have become a major problem of worldwide concern. Yeasts belonging to the Candida genus and the pathogenic fungus Cryptococcus neoformans are responsible for different clinical manifestations, especially in immunocompromised patients. Antifungal therapies are currently based on a few chemotherapeutic agents that have problems related to effectiveness and resistance profiles. Microemulsions are isotropic, thermodynamically stable transparent systems of oil, water and surfactant that can improve the solubilization of lipophilic drugs. Taking into account the need for more effective and less toxic drugs along with the potential of thiophene derivatives as inhibitors of pathogenic fungi growth, this study aimed to evaluate the antifungal activity of a thiophene derivative (5CN05) embedded in a microemulsion (ME). The minimum inhibitory concentration (MIC) was determined using the microdilution method using amphotericin B as a control. The formulations tested (ME- blank and ME-5CN05) showed physico-chemical properties that would allow their use by the topical route. 5CN05 as such exhibited moderate or weak antifungal activity against Candida species (MIC = 270-540 μg.mL⁻¹) and good activity against C. neoformans (MIC = 17 μg.mL⁻¹). Candida species were susceptible to ME-5CN05 (70-140 μg.mL⁻¹), but C. neoformans was much more, presenting a MIC value of 2.2 μg.mL⁻¹. The results of this work proved promising for the pharmaceutical industry, because they suggest an alternative therapy against C. neoformans.

Key words: antifungal susceptibility, Cryptococcus neoformans, microemulsion, thiophene derivatives.
Candida yeasts are microorganisms belonging to the normal microbiota of healthy individuals, mainly in the oral mucosa, the gastrointestinal tract and the female genitourinary tract (Shao, Sheng and Zhang, 2007). However, these fungi are responsible for different clinical manifestations, especially in immunocompromised patients, ranging from skin and mucous infections to systemic infections (Sardi et al., 2013). Their importance comes from the high frequency with which they colonize and infect the human host (De Bernardis et al., 2004), being the fourth most common pathogens associated with cases of nosocomial infection (Wisplinghoff et al., 2004).

Cryptococcus neoformans is an encapsulated fungus capable of causing infections in immunocompromised patients (Carroll et al., 2012; Guerra et al., 2012). Inhalation of its basidiospores or cells present in the environment can result in lung infection and its subsequent spread to the central nervous system, causing meningoencephalitis, recognized as one of the most important opportunistic infections in patients with HIV with a worldwide incidence of approximately 957,000 cases per year (Leongson et al., 2013).

Conventional treatments of fungal diseases are currently based on a few chemotherapeutic agents such as azoles and polyenes, which have serious problems related to effectiveness, activity spectrum, toxicity, low power and inadequate pharmacokinetics (Scotti et al., 2012). Moreover, the occurrence of microbial resistance to antimicrobial agents is shown to be a growing public health problem worldwide and the biggest obstacle to the success of a treatment, as it continues to reduce the number of drugs available in the market (Oliveira and Silva, 2008; Benghezal et al., 2007). This scenario demonstrates the need for the development of new antifungal agents as therapeutic alternatives to control fungal infections.

Organic compounds containing aromatic heterocyclic rings such as thiophene are widely distributed in nature and are generally of great importance in many biochemical processes, having a broad spectrum of pharmacological properties (Mohammad et al., 2012). The versatile applicability in syntheses and the biological activity of these heterocycles make them important structural fragments in synthetic medicinal chemistry, serving as a basis for planning and implementation of new therapeutic agents (Meotti et al., 2003). For the present work, it was synthesized a derivative of 2-amino thiophene, namely the 2-[(3,4-dichloro-benzylidene)-amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carbonitrile, referred to as 5CN05 (Figure 1). This compound belongs to a series of synthetic thiophene derivatives with well-proven antifungal activity in vitro (Mendonça Junior et al., 2011). Its biopharmaceutical characteristics are not yet well understood, especially with respect to permeability. However, the high value of its partition coefficient (logP = 5.98) suggests that it has poor water solubility and permeability.

A microemulsion (ME) is a thermodynamically stable and optically transparent system made up of a mixture of two immiscible liquids stabilized by an interfacial surfactant film. The specific properties of microemulsified systems are primarily related to their low interfacial tension, large interfacial area, small size of droplets, low viscosity and high solubilization power for lipophilic, hydrophilic and amphiphilic drugs (Damasceno et al., 2011; Fanun, 2012; Silva et al., 2009b). MEs usually contain high concentrations of surfactants, an essential factor for successful incorporation of poorly water soluble drugs (Damasceno et al., 2012; Djekic et al., 2012). These systems have the ability to deliver water insoluble compounds by carrying the drugs in their oil core or on the water-oil interface. This biological property allows the use of MEs as biotechnological carriers for large water insoluble molecules such as those of the tiophene derivatives.

The treatment of fungal infections by topical dosage forms shows some advantageous features such as possibility of action at the application site and reduction of the risk of systemic side effects, increased efficacy of the therapy and its acceptance by the patients (Güngör, Erdal and Aksu, 2013). In topical formulations, MEs have proven effective in increasing the absorption of both hydrophilic and lipophilic drugs by the skin when compared to conventional systems such as emulsions and aqueous solutions (Grampurohit, Ravikumar and Mallya, 2011). The use of MEs may also increase the local or systemic action of drugs by different mechanisms, thereby representing an interesting alternative to antifungal drugs (Jadhav, Shetye and Kadam, 2010).

A microemulsion (ME) is a thermodynamically stable and optically transparent system made up of a mixture of two immiscible liquids stabilized by an interfacial surfactant film. The specific properties of microemulsified systems are primarily related to their low interfacial tension, large interfacial area, small size of droplets, low viscosity and high solubilization power for lipophilic, hydrophilic and amphiphilic drugs (Damasceno et al., 2011; Fanun, 2012; Silva et al., 2009b). MEs usually contain high concentrations of surfactants, an essential factor for successful incorporation of poorly water soluble drugs (Damasceno et al., 2012; Djekic et al., 2012). These systems have the ability to deliver water insoluble compounds by carrying the drugs in their oil core or on the water-oil interface. This biological property allows the use of MEs as biotechnological carriers for large water insoluble molecules such as those of the tiophene derivatives.

The treatment of fungal infections by topical dosage forms shows some advantageous features such as possibility of action at the application site and reduction of the risk of systemic side effects, increased efficacy of the therapy and its acceptance by the patients (Güngör, Erdal and Aksu, 2013). In topical formulations, MEs have proven effective in increasing the absorption of both hydrophilic and lipophilic drugs by the skin when compared to conventional systems such as emulsions and aqueous solutions (Grampurohit, Ravikumar and Mallya, 2011). The use of MEs may also increase the local or systemic action of drugs by different mechanisms, thereby representing an interesting alternative to antifungal drugs (Jadhav, Shetye and Kadam, 2010).

Figure 1 - Chemical structure of 5CN05 molecule.
In this context, the present study aims to evaluate the antifungal activity of 5CN05 embedded in a ME for topical use, by determination of its minimum inhibitory concentration against pathogenic yeast species.

Materials and Methods

Preparation of microemulsion formulation and incorporation of 5CN05

To obtain microemulsions (MEs), pseudoternary phase diagrams (PTPD) were constructed using a surfactant blend of LAS® (Brasquim, São Paulo - SP, Brazil) and Plurol Oleique® (Gattefossé, Saint-Priest, France), and isopropyl myristate as oil phase (Via Farma, São Paulo - SP, Brazil). Purified water was produced by a reverse osmosis purification system, model OS10LX (Gehaka, São Paulo - SP, Brazil). For 5CN05 incorporation in ME, such a drug was initially dispersed in the oil phase, and the remaining components were added, including water. This multiphase mixture was then subjected to three 1 min-alternate homogenization cycles by an ultrasound bath, model USC-3300 (Unique). The formulation obtained, called ME-5CN05, was characterized for its macroscopic appearance, pH, electrical conductivity and refractive index, and compared to that without drug (ME-blank).

Target microorganisms

The antifungal activity of ME-5CN05 and ME-blank systems was assessed using standard strains from the American Type Culture Collection (ATCC), namely Candida albicans ATCC 18804, Candida parapsilosis ATCC 22019 and Candida tropicalis ATCC 13803, provided by the Laboratory of Drug Development and Testing (LABDEM) belonging to the State University of Paraíba. Their activity was also assessed against Cryptococcus neoformans (LM10), provided by the Mycology Laboratory of the Federal University of Paraíba.

Determination of Minimum Inhibitory Concentration

The Minimum Inhibitory Concentration (MIC) of MEs was determined by the microdilution method using 96-well microplates, consisting of serial dilution either of drug and or the ME-5CN05 and ME-blank formulations, prepared following the guidelines of the Clinical and Laboratory Standards Institute, rule CLSI M27-A3 for yeasts. 5CN05 was dissolved in LAS® at a concentration of 2175 μg.mL⁻¹ and then tested at concentrations ranging from 8 to 1088 μg.mL⁻¹. Amphotericin B (AmB) was used as reference at concentrations from 2 to 0.015 μg.mL⁻¹. The possible activity of LAS® was evaluated as well, using the broth without inoculum as a negative control.

To prepare inocula, microbial suspensions were standardized in tubes containing 5 mL of 0.9% sterile saline solution and adjusted spectrophotometrically to 90% transmittance at 530 nm, corresponding to a concentration of 106 cfu.mL⁻¹. Samples were serially diluted in the microdilution wells containing 100 μL of Sabouraud-Dextrose broth (Hi Media, Sasti - Maharashtra, India). After addition of inoculum (100 μL) in separate plates for each yeast, the plates were incubated at 35 ± 1 °C for 24 h and visually evaluated. The MIC corresponded to the lowest sample dilution capable of providing growth inhibition of yeasts. All tests were performed in duplicate.

Results

Figure 2 shows the phase diagram characterizing the phase behavior of surfactants blends, namely the oil and water phases. It is noteworthy the existence of a variety of states, highlighting the presence of microemulsion formation areas, which are regions where the energy used and the components proportions were suitable to reduce the interfacial tension until the formation of a homogeneous, clear and translucent system (Silva et al., 2009a).

The composition of MEs was 35.3% w/w LAS®, 17.5% w/w Plurol Oleique®, 5.9% w/w isopropyl myristate and 41.2% w/w water. The ME-blank formulation was shown to be a translucent, slightly yellowish solution with slightly viscous appearance, while the addition of the drug at a concentration of 560 μg.mL⁻¹ to prepare the ME-5CN05 formulation did not modify its translucent appearance and consistency (as confirmed by rheological characterization studies - data not shown), differing mainly in the color. Table 1 summarizes the main results of physico-chemical characterization tests performed on both formulations.

As expected, the tests of Minimum Inhibitory Concentration (MIC) either for the drug or MEs, whose results are listed in Table 2, showed a clear growth of all the yeasts only in the controls containing the inocula in addition to the culture medium, hence confirming the suitability of the selected conditions.

All the microorganisms studied proved sensitive to 5CN05, which showed moderate activity against Candida species (MIC = 270-540 μg.mL⁻¹) and an activity more than one order of magnitude greater against Cryptococcus neoformans (MIC = 17 μg.mL⁻¹), while the MIC value for the positive control (AmB) was only 0.5 μg.mL⁻¹.

As far as the MEs are concerned, microorganisms did not show any sensitivity to ME-blank, while ME-5CN05 proved excellent activity against Candida species, mainly C. albicans and C. parapsilosis (MIC = 70 μg.mL⁻¹), and excellent activity against C. neoformans (MIC = 2.2 μg.mL⁻¹).
Discussion

All MEs were handled and maintained at room temperature for 48 h before their characterization. Under these conditions, all formulations exhibited a homogeneous appearance, without any evidence of phase separation or precipitate formation. As is well known, the optimum pH of a topical formulation must be selected so as to maximize the stability of active components and the tolerance of the skin, being acceptable values between 5.5 and 8.0 (Silva et al., 2009a). The pH values shown for ME-blank and ME-5CN05 were within this range, which would allow the topical application of the ME-5CN05 system. Moreover, this parameter was not influenced by the addition of 5CN05.

The use of topical MEs to improve the antifungal activity of drugs is a strategy adopted by some researchers. For instance, Jadhav, Shetye and Kadam (2010), developing MEs containing topical fluconazole, observed greater activity of their formulations than conventional gels available in the market, a fact that was attributed to the better diffusion of the drug provided by the presence of surfactants and oil phase. El-Hadidy et al. (2012), investigating the application of MEs as topical carriers for voriconazole, observed that their antifungal activity against C. albicans was considerably higher than that of a supersaturated solution of the same drug.

![Pseudo ternary phase diagram for the LAS™/Plurol Oléique® surfactant blend (S) at the proportion of 2:1, isopropyl myristate (O) and water (W) system. The marked areas represent: PS - phase separation; MWLE - milky white liquid emulsion; OLE - opaque liquid emulsion; ME - microemulsion; - ME-blank formulation.](image)

**Table 1 - Physico-chemical characterization of ME-blank and ME-5CN05.**

| Parameters          | ME-blank       | ME-5CN05       |
|---------------------|----------------|----------------|
| Macroscopic appearance | Limpid        | Limpid         |
| Color               | Slightly yellow | Strong yellow  |
| pH                  | 6.60 ± 0.03    | 6.58 ± 0.03    |
| Conductivity (µS.cm⁻¹) | 105.00 ± 5.80 | 97.23 ± 1.38   |
| Refractive index    | 1.410 ± 0.02   | 1.412 ± 0.01   |

**Table 2 - Values of MIC determined either for the drug alone (5CN05) or for MEs with (ME-5CN05) and without (ME-blank) the drug.**

| Microorganism          | MIC (µg.mL⁻¹) |
|------------------------|---------------|
|                        | 5CN05 | ME-blank | ME-5CN05 |
| *Candida albicans* ATCC 18804 | 270     | R         | 70        |
| *C. parapsilosis* ATCC 22019 | 270     | R         | 70        |
| *C. tropicalis* ATCC 13803 | 540     | R         | 140       |
| *Cryptococcus neoformans* LM10 | 17      | R         | 2.2       |

R = resistant.
5CN05, either as such or in ME, showed greater activity against \textit{C. neoformans} than against \textit{Candida} spp. This activity profile is in agreement with the results of Mendonça Junior et al. (2011), who found that tiophene derivatives have moderate or weak antifungal activity against \textit{Candida} strains and high activity against \textit{C. neoformans}.

Nowadays, fungal infections are treated using a limited number of therapeutic agents, among which the main are echinocandins, polyenes (AmB), antimetabolites (flucytosine) and azoles (fluconazole), but only the last three have activity against \textit{C. neoformans} (Hast et al., 2011). Despite its wide use, AmB has high nephrotoxicity and hepatotoxicity and may cause severe anemia (Tonomura et al., 2009). Azoles are the drugs of choice in the therapy of infections caused by \textit{Cryptococcus} spp., but, although there is no report, as far as we are aware, on \textit{C. neoformans} resistance to usual antifungals yet, it is certain that less susceptible strains will arise as a result of the extensive use of fluconazole in long-term or maintenance therapies (Guerra et al., 2012).

One of the most important factors of \textit{C. neoformans} virulence is its polysaccharide capsule that has in its composition two different polysaccharides (90-95% of glucuronoxylomannan and 5-8% of galactoxylomannan) and mannoproteins (Vecchiarello and Monari, 2012). This fungus has the ability to modulate the structure and size of its capsule during the infection so as to allow its adaptation to different environments and to make its dissemination in different tissues easier (Charlier et al., 2005). Such structural changes in the capsule have been reported as an important factor for the microorganism crossing of the blood-brain barrier (Guerrero et al., 2006; Jain, Guerrero and Fries, 2006). Therefore, one can assume that the activity of 5CN05, after its incorporation into a ME, is probably related to the interaction between lipid components of the system and fungal capsule, thereby increasing the contact area and making the drug access to the microorganism easier. Finally, we believe that the ME-5CN05 formulation developed in this work may act as a facilitator of drug permeation through the capsular material of \textit{C. neoformans}.

The results of this work could be of some concern for the pharmaceutical industry, because they suggest an alternative therapy against \textit{C. neoformans}.

Acknowledgments

This work was supported by PROCAD, Project No: 552652/2011-3, Development of Processes and Pharmaceutical and Biotechnological Processes Using the Sustainability Potential of Semiard. The authors also acknowledge the Coordination of High-Level Personnel Training (CAPES), linked to the Brazilian Ministry of Education, for financial support of Prof. A. Converti as Special Visiting Researcher (Science without Borders Program, project n. 2609/2013), the State of São Paulo Research Foundation (FAPESP- Process n°: 2013/22212-0), the National Council for Scientific and Technological Development (CNPq) and the Center for Strategic Technology in the Northeast (CETENE) and Edital PROPESQ-UEPB nº 02/2010.

References

Benghezal M, Adam E, Lucas A, Burn C, Orchard MG, Deuschel C, Valentino E, Braillard S, Paccaud JP, Cosson P (2007) Inhibitors of bacterial virulence identified in a surrogate host model. Cell Microbiol 9:1336-1342.

Carroll SF, Lafferty EI, Flacey A, Fujiwara TM, Homer R, Morgan K, Loredo-Osti JC, Qureshi ST (2012) Susceptibility to progressive \textit{Cryptococcus neoformans} pulmonary infection is regulated by loci on mouse chromosomes 1 and 9. Infect Immun 80:4167-4176.

Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F (2005) Capsule structure changes associated with \textit{Cryptococcus neoformans} crossing of the blood-brain barrier. Am J Pathol 166:421-32.

Damasceno BPGL, Silva JA, Oliveira EE, Silveira WLL, Araújo IB, Oliveira AG, Egipto EST (2011) Microemulsão: Um promissor carreador para moléculas insolúveis. Rev Cienc Farm Básica Apl 32:9-18.

Damasceno BPGL, Dominici VA, Urbano IA, Silva JA, Santos-Magalhães NS, Silva, AKA, Medeiros AC, Oliveira AG, Egipto EST (2012) Amphotericin B microemulsion reduces toxicity and maintains the efficacy as an antifungal product. J Biomed Nanotechnol 8:290-300.

De Bernardis F, Tacconelli E, Mondello F, Cataldo A, Arancia S, Cauda R, Cassone A (2004) Antiretroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by \textit{Candida albicans} without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. FEMS Immunol Med Microbiol 41:27-34.

Djekic L, Primorac M, Filipic S, Agbaba D (2012) Investigation of surfactant/cosurfactant synergism impact on ibuprofen solubilization capacity and drug release characteristics of nonionic microemulsions. Int J Pharm 433:25-33.

El-Hadidy GN, Ibrahim HK, Mohamed MI, El-Milligi MF (2012) Microemulsions as vehicles for topical administration of voriconazole: Formulation and in vitro evaluation. Drug Dev Ind Pharm 38:64-72.

Espinell-Ingroff A (2009) Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: A review of the literature (2005-2009). Revista Iberoamericana de Micología 26:15-22.

Fanun M (2012) Microemulsions as delivery systems. Curr Opin Colloid Interface Sci 17:306-313.

Grampurohit N, Ravikumar P, Mallya R (2011) Microemulsions for topical use - a review. Indian Journal of Pharmaceutical Education and Research 45:100-107.

Guerra CR, Ishida K, Nucci M, Rozental S (2012) Terbinafine inhibits \textit{Cryptococcus neoformans} growth and modulates fungal morphology. Mem Inst Oswaldo Cruz 107:582-90.

Guerrero A, Jain N, Goldman DL, Fries B.C. (2006). Phenotypic variation of the Cryptococcus neoformans capsule during the infection so as to allow its adaptation to gus has the ability to modulate the structure and size of its ronoxylomannan and 5-8% of galactoxylomannan) and position two different polysaccharides (90-95% of glucu-
Hast MA, Nichols CB, Armstrong S, Kelly SM, Hellinga HW, Alspaugh JA, Beese, LS (2011) Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens. J Biol Chem 286:35149-35162.

Jadhav KR, Shetye SL, Kadam VJ (2010) Design and evaluation of micro emulsion based drug delivery system. Asian J Exp Biol Sci 1:580-591.

Jain N, Guerrero A, Fries BC (2006) Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans. FEMS Yeast Res 6:480-488.

Leongson K, Cousineau-Côté V, Goupil M, Aumont F, Sénéchal S, Gaboury L, Jolicoeur P, Kronstad JW, Repentigny L (2013) Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene. Infect Immun 81:1100-1113.

Mendonça Junior FJB, Lima-Neto RG, Oliveira TB, Lima MCA, Pitta IR, Galdino SL, Cruz RMD, Araújo RSA, Neves RP (2011) Synthesis and evaluation of the antifungal activity of 2-(substituted-amino)-4,5-dialkyl-thiophene-3-carbonitrile derivatives. Lat Am J Pharm 30:1492-1499.

Mootti FC, Silva DO, Santos ARS, Zeni G, Rocha JBT, Nogueira CW (2003) Thiophenes and furans derivatives: A new class of potential pharmacological agents. Environ Toxicol Pharmacol 15:37-44.

Mohammad AlC, Satyendra D, Aupurba T, Patel M, Monika K, Girish K, Mohan S, Saravanjan J (2012) Synthesis and antimicrobial screening of some novel substituted thiophenes. Hygeia 4:112-118.

Oliveira AC, Silva RS (2008) Desafios de cuidar em saúde frente à resistência bacteriana: Uma revisão. Revista Eletrônica de Enfermagem 10:189-197.

Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS (2013) Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62:10-24.

Scotti L, Scotti MT, Lima EO, Silva MS, Lima MCA, Pitta IR, Moura RO, Oliveira JGB, Cruz RMD, Mendonça Junior, FJB (2012) Experimental methodologies and evaluations of computer-aided drug design methodologies applied to a series of 2-aminothiophene derivatives with antifungal activities. Molecules 17:2298-315.

Shao LC, Sheng CQ, Zhang WN (2007) Recent advances in the study of antifungal lead compounds with new chemical scaffolds. Yaoxue Xuebao 42:1129-1136.

Silva JA, Santana DP, Bedor DGC, Borba VFC, Lira AAM, Egito EST (2009a) Estudo de liberação e permeação in vitro do diclofenaco de dietilamônio em microemulsão gel-like. Quim Nova 32:1389-1393.

Silva JA, Bedor DGC, Damasceno BPGL, Oliveira AG, Egito EST, Santana DP (2009b) Physicochemical characterization and development of a microemulsion system for transdermal use. J Dispersion Sci Technol 31:1-8.

Tonomura Y, Yamamoto E, Kondo C, Itoh A, Tsuchiya N, Uehara T, Babahuman T (2009) Amphotericin B-induced nephrotoxicity: Characterization of blood and urinary biochemistry and renal morphology in mice. Hum Exp Toxicol 28:293-330.

Vecchiarelli A, Monari C (2012) Capsular material of Cryptococcus neoformans: Virulence and much more. Mycopathologia 173:375-386.

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases 39:309-317.

All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License CC BY-NC.